Eli Lilly Stock Today

<div class='circular--portrait' style='background:#006400;color: #FFE4E1;font-size:4em;padding-top: 25px;;'>EL</div>
Eli Lilly is trading at 163.88 as of the 15th of July 2020; that is 1.07 percent increase since the beginning of the trading day. The stock's open price was 162.15. Eli Lilly has less than a 11 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 30 trading days. Equity ratings for Eli Lilly And are calculated daily based on the scoring framework. The performance scores are derived for the period starting the 16th of April 2020 and ending today, the 15th of July 2020. Click here to learn more.
Analyze Filter   Report: 30th of July 2020

   Performance
3 100 

   Odds of Distress
11  

Eli Lilly Profile

The upcoming quarterly report is expected on the 30th of July 2020. Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company was founded in 1876 and is headquartered in Indianapolis, Indiana. Eli Lilly operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 33815 people. more on Eli Lilly
Eli Lilly Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Eli Lilly And SEC Filings
Eli Lilly SEC Filings
Security & Exchange Commission EDGAR ReportsView All
Legal NameEli Lilly And
Older SymbolLLY
PresidentJoshua SmileyView All
Thematic Classifications
Active investing themes Eli Lilly currently participates. An investing theme is an unweighted collection of funds, stocks, ETFs or cryptocurrencies
    Macroaxis Picks
    Drugs
showing 2 out of 4 themes  View All
Average Analyst Recommendation
Current trade recommendation based on an ongoing consensus estimate among financial analysis covering Eli Lilly And. The Eli Lilly consensus assessment is calculated by taking the average estimates from all of the analysts covering Eli Lilly
Piotroski F Score
Academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Eli Lilly And financial position. Scores of 8 and 9 are usually clasified strong value stocks whereas scores of 2 or below are considered weak value stocks.
 5 - HealthyDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares943.8 M931.1 M
Fairly Up
Decreasing
Slightly volatile
Weighted Average Shares Diluted935.9 M935.7 M
Slightly Up
Decreasing
Slightly volatile
Net Cash Flow from Operations4.8 B4.8 B
Fairly Down
Decreasing
Stable
Total Assets41.8 B39.3 B
Notably Up
Increasing
Slightly volatile
Total Liabilities33.1 B36.6 B
Moderately Down
Increasing
Slightly volatile
Current Assets15.7 B13.7 B
Fairly Up
Increasing
Slightly volatile
Current Liabilities11.8 B11.8 B
Slightly Up
Increasing
Slightly volatile
Total Debt13.2 B15.3 B
Fairly Down
Increasing
Slightly volatile
Return on Average Assets0.230.216
Notably Up
Increasing
Very volatile
Gross Margin0.740.788
Notably Down
Decreasing
Slightly volatile
Asset Turnover0.570.58
Fairly Down
Decreasing
Slightly volatile
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Eli Lilly available fundamental, technical, and predictive indicators. Current horizon is 30 days (very short) - details
Strong HoldOvervalued
Financial Strength
Eli Lilly financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Eli Lilly success along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
AA- ( Average Bond Rating ) Very Strong
  Operating Cash Flow
Eli Lilly And (LLY) is traded on BATS Exchange in USA. It is located in Lilly Corporate Center, Indianapolis, IN 46285, United States and employs 33,815 people. Eli Lilly And was previously known as ELI LILLY Co and was traded on BATS Exchange under the symbol LLY. Eli Lilly is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with total capitalization of 159.2 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Eli Lilly's market, we take the total number of its shares issued and multiply it by Eli Lilly's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Eli Lilly And runs under Healthcare sector within Drug Manufacturers?General industry. The entity has 956.45 M outstanding shares of which 6 M shares are now shorted by investors with about 1.46 days to cover shorted positions. Eli Lilly And has about 1.8 B in cash with 4.91 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.98.
Check Eli Lilly Probability Of Bankruptcy

Ownership Allocation (%)

Eli Lilly Stock Price Odds Analysis

Odds Down 163.88HorizonTargetOdds Up 163.88
88.71%30 days
 163.88 
11.15%
Based on a normal probability distribution, the odds of Eli Lilly to move above the current price in 30 days from now is about 11.15 (This Eli Lilly And probability density function shows the probability of Eli Lilly Stock to fall within a particular range of prices over 30 days) .

Eli Lilly Income Statement Over Time

Eli Lilly And Income Statement is one of the three primary financial statements used for reporting Eli Lilly's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Eli Lilly And revenue and expense. Eli Lilly Income Statement primarily focuses on the company's revenues and expenses during a particular period. Eli Lilly Consolidated Income is fairly stable at the moment as compared to the past year. Eli Lilly reported Consolidated Income of 8.32 Billion in 2019. Cost of Revenue is likely to grow to about 5.3 B in 2020, whereas Direct Expenses is likely to drop slightly above 4.7 B in 2020. View More Fundamentals

Eli Lilly Stock Against Markets

Did you try this?

Run Companies Directory Now

   

Companies Directory

Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
All  Next Launch Module

Eli Lilly Upcoming and Recent Events

Eli Lilly Company Earnings Announcements Dates

Upcoming Quarterly Report30th of July 2020
Next Earnings Report28th of October 2020
Next Fiscal Quarter End30th of June 2020
Next Fiscal Year End4th of February 2021
Last Quarter Report31st of March 2020
Last Earning Announcement30th of June 2019

Eli Lilly Corporate Filings

Eli Lilly SEC Reporting

Submission of Matters to a Vote of Security Holders
View
Financial Statements and Exhibits. Other Events
View
Unclassified Corporate Event
View

Eli Lilly Distributions to stockholders

A dividend is the distribution of a portion of Eli Lilly earnings, decided and managed by the Eli Lillys board of directors and paid to a class of its shareholders. Note, announcements of dividend payouts are generally accompanied by a proportional increase or decrease in a company's stock price. Eli Lilly dividend payments follow a chronological order of events, and the associated dates are important to determine the shareholders who qualify for receiving the dividend payment.
14th of May 2020
13th of February 2020
14th of November 2019
14th of August 2019
16th of May 2019
14th of February 2019
14th of November 2018
14th of August 2018

Eli Lilly Corporate Directors

Ellen Marram Lead Independent Director
Kathi Seifert Independent Director
Ralph Alvarez Independent Director
Additionally, see Stocks Correlation. Please also try Aroon Oscillator module to analyze current equity momentum using aroon oscillator and other momentum ratios.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page